
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Market Cap
$639M
Revenue
$90M
P/E Ratio
N/A
P/B Ratio
-51.87
D/E Ratio
-14.02
Dividend Yield
0.00%
PEG Ratio
0.22
Net Income
-$127M
Net Profit Margin
-140.35%
Beta
0.398
Gross Margin
0.90%
R/S Growth
5.05
52W Low
$0.00
52W High
$0.00
Updated: July 9 at 19:28:57